RAC, CTE, ADO: ASX health stocks with massive returns in past 3 years

Be the First to Comment Read

RAC, CTE, ADO: ASX health stocks with massive returns in past 3 years

Multibagger stocks provide multiple times return
Image source: © Zsoltercse   | Megapixl.com

Highlights

  • Multibagger stocks provide multiple times price return compared to their initial investment value
  • These stocks have strong fundamentals; however, they are undervalued
  • Business with a large scope of growth in a short period are potential multibaggers

Multibaggers are lucrative stocks that provide returns several times higher than their initial investment value. To be more specific, if a stock price rises by double, it's called a double bagger, while if the price grows multiple times, it's called a multibagger.

These stocks are usually undervalued and have strong fundamentals. Generally, businesses with huge room for growth in a short period can be considered as multibagger stocks.

This article will discuss three healthcare stocks from ASX that have provided a price return of multiple times their initial invested value.

Race Oncology Limited (ASX:RAC)

Race Oncology is a precision oncology company, currently involved in exploring the use of a cancer drug called Zantrene® as a new therapy for melanoma and clear cell renal cell carcinoma.

Image source: © 2022 Kalkine Media®

RAC has a market capitalisation of AU$298.51 million, and its share price has surged by nearly 2611% in the last three years.

Do read: ALT and CDX: Why these ASX healthcare stocks were in news today

Cryosite Limited (ASX: CTE)

Clinical trial in laboratory

Image source: © MinervaStudio   | Megapixl.com

Cryosite Limited is a fast-growing company which offers outsourced clinical trial logistic services.  It has 20 years of experience in managing clinical trial supply chains, including importation and storage of products.

In the half-year ended 31 December 2021, the company's profit after tax increased by a massive 175%. Similarly, cash on hand increased by AU$1.393M to AU$5.274M These results reaffirm the company’s growth profile established over the past three years.

Shares of CTE have provided a lucrative price return of about 1961% in the past three years and the company has a market cap of AU$33.19 million.

Also read: WFL, OSL, AVE: Three ASX healthcare stocks with over 20% QTD returns

AnteoTech Ltd (ASX: ADO)

AnteoTech, a surface chemistry company, has a market capitalisation of AU$208.83 million. The company's core technology product groups comprise AnteoCoat™, AnteoBind™ and AnteoRelease™.

Recently, ADO registered an updated EuGeni COVID-19 Rapid Antigen Test (RAT) in Europe under the In Vitro Diagnostic Directive (IVDD) 98/79/EC Regulations. This will offer an additional advantage to ADO as it develops the EuGeni COVID-19 RAT footprint in Europe.

Shares of Anteotech have prospered by nearly 629.5% in the last three years.

Embed video

 

Multibaggers are lucrative stocks that provide returns several times higher than their initial investment value. To be more specific, if a stock price rises by double, it's called a double bagger, while if the price grows multiple times, it's called a multibagger.

These stocks are usually undervalued and have strong fundamentals. Generally, businesses with huge room for growth in a short period can be considered as multibagger stocks.

Disclaimer

Speak your Mind

Featured Articles

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK